MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
Ryohei Yoshida(Asahikawa Medical University), David A. Barbie(Dana-Farber Cancer Institute), Benjamin F. Springer(Dana-Farber Cancer Institute), Marco Campisi(Dana-Farber Cancer Institute), Ravindra Uppaluri(Dana-Farber Cancer Institute), Yurie Yamamoto(Osaka City University), Tetsuo Tani(Keio University), Yoshihisa Kobayashi(Harvard University), Shriram K. Sundararaman(Beth Israel Deaconess Medical Center), Pasi A. Jänne(Harvard University), Hirofumi Shibata(Kyoto University), Maria Saigí(Institut Català d'Ornitologia), Cloud P. Paweletz(Massachusetts General Hospital), Shunsuke Kitajima(Japanese Foundation For Cancer Research), Tran C. Thai(Dana-Farber Cancer Institute), Koji Haratani(Dana-Farber Cancer Institute), Patrick H. Lizotte(Harvard University), William Kim(University of San Diego), Prafulla C. Gokhale(Harvard University), Amir Vajdi(Dana-Farber Cancer Institute), Navin R. Mahadevan(Brigham and Women's Hospital), Juan J. Miret(Dana-Farber Cancer Institute), Israel Cañadas(Fox Chase Cancer Center), Erik H. Knelson(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 38
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k